(4-cyano-phenylamino)-(3-ethoxy-5-hydroxy)-acetic acid methyl ester | 871345-31-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (4-cyano-phenylamino)-(3-ethoxy-5-hydroxy)-acetic acid methyl ester
• 英文别名: methyl (RS)-(4-cyano-phenylamino)-(3-ethoxy-5-hydroxy-phenyl)-acetate；methyl 2-(4-cyanoanilino)-2-(3-ethoxy-5-hydroxyphenyl)acetate
• CAS: 871345-31-2
• 化学式: C₁₈H₁₈N₂O₄
• 分子量: 326.352
• InChiKey: QDWBETNWWRRTII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  91.6
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (4-cyano-phenylamino)-(3-ethoxy-5-hydroxy)-acetic acid methyl ester 在 四(三苯基膦)钯 、 TEA 、 potassium carbonate 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 生成 Methyl 2-(4-cyanoanilino)-2-(3-ethoxy-5-phenylphenyl)acetate
  参考文献：
  名称：

  Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

  摘要：

  We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor Vila inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.079
• 作为产物：
  描述：

  3,5-二羟基苯甲醇 在 palladium on activated charcoal manganese(IV) oxide 、 水 、 氢气 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (4-cyano-phenylamino)-(3-ethoxy-5-hydroxy)-acetic acid methyl ester
  参考文献：
  名称：

  Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors

  摘要：

  We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor Vila inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.079

文献信息

• N-(4- carbamimidoyl-phenyl) -glycine derivatives
  申请人：——

  公开号：US20010001799A1

  公开（公告）日：2001-05-24

  The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: 1 wherein R 1 , E, X 1 to X 4 and G 1 and G 2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.

  这项发明涉及一种新颖的公式为N-(4-羰基苄基)-甘氨酸衍生物，其中R1、E、X1至X4以及G1和G2如描述和权利要求中所定义，以及其水合物或溶剂合物和生理可用盐。
• N- (4-carbamimidoyl-phenyl) -glycine derivatives
  申请人：——

  公开号：US20030083504A1

  公开（公告）日：2003-05-01

  The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: 1 wherein R 1 , E, X 1 to X 4 and G 1 and G 2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.

  本发明涉及一种新的N-(4-氨基甲酰基苯基)-甘氨酸衍生物，其化学式为：1，其中R1、E、X1至X4和G1和G2如说明书和权利要求所定义，以及其水合物或溶剂化合物和生理上可用的盐。
• N-(4-carbamimidoyl-phenyl)-glycine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06242644B1

  公开（公告）日：2001-06-05

  The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.

  本发明涉及一种新的公式为：其中R1、E、X1到X4以及G1和G2如描述和权利要求中所定义的N-(4-羧酰基苯基)-甘氨酸衍生物，以及其水合物或溶剂化物和生理上可用的盐。
• Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity
  作者：Katrin Groebke Zbinden、David W. Banner、Kurt Hilpert、Jacques Himber、Thierry Lavé、Markus A. Riederer、Martin Stahl、Thomas B. Tschopp、Ulrike Obst-Sander

  DOI：10.1016/j.bmc.2006.03.042

  日期：2006.8

  The discovery of a highly potent and selective tissue factor/factor VIIa inhibitor is described. Upon oral administration of its double prodrug in the guinea pig, a dose-dependent antithrombotic effect is observed in an established model of arterial thrombosis without prolonging bleeding time. The pharmacodynamic properties of this selective inhibitor are compared to the behaviour of a mixed factor VIIa/factor Xa inhibitor. (c) 2006 Elsevier Ltd. All rights reserved.
• Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors
  作者：Katrin Groebke Zbinden、Ulrike Obst-Sander、Kurt Hilpert、Holger Kühne、David W. Banner、Hans-Joachim Böhm、Martin Stahl、Jean Ackermann、Leo Alig、Lutz Weber、Hans Peter Wessel、Markus A. Riederer、Thomas B. Tschopp、Thierry Lavé

  DOI：10.1016/j.bmcl.2005.04.079

  日期：2005.12

  We describe the structure-based design and synthesis of highly potent, orally bioavailable tissue factor/factor Vila inhibitors which interfere with the coagulation cascade by selective inhibition of the extrinsic pathway. (c) 2005 Elsevier Ltd. All rights reserved.